8-K: Century Therapeutics Reports Positive Q1 2025 Financial Results and Advances Clinical Pipeline

Century Therapeutics reports first quarter 2025 financial results, highlighting patient dosing in the Phase 1 CALiPSO-1 trial and progress in preclinical programs.

Summary

• Century Therapeutics announced its first quarter 2025 financial results and provided a business update.
• Patient dosing has begun in the Phase 1 CALiPSO-1 trial for CNTY-101 in autoimmune disease, with expansion to additional U.S. and European sites planned.
• CNTY-308 is expected to enter IND-enabling studies in mid-2025 to support clinical trials in B-cell-mediated autoimmune diseases and malignancies.
• The company presented preclinical pipeline data at the ASGCT 28th Annual Meeting, focusing on iPSC-derived tunable CD4+/CD8+ ab T cells and Allo-Evasion 5.0 technology.
• Collaboration revenue for the quarter was $109.2 million due to the termination of the Bristol-Myers Squibb agreement.
• Cash, cash equivalents, and marketable securities totaled $185.8 million as of March 31, 2025, which is expected to fund operations into the fourth quarter of 2026.
• Net income for the quarter was $76.6 million, compared to a net loss of $28.1 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting clinical trial progress, preclinical advancements, and a strong cash position. The one-time revenue boost from the terminated collaboration agreement contributes to the positive sentiment, although the termination itself could be viewed as a potential long-term negative.

Positives

• Patient dosing has begun in the Phase 1 CALiPSO-1 trial for CNTY-101.
• CNTY-308 is expected to enter IND-enabling studies in mid-2025.
• The company's CTA has been authorized in Germany, France, and Italy.
• Clinical data for CNTY-101 is expected by the end of 2025.
• The company has a strong cash position of $185.8 million, expected to fund operations into Q4 2026.
• Net income was $76.6 million for the quarter.

Negatives

• The Collaboration Agreement with Bristol-Myers Squibb was terminated, although this resulted in a one-time revenue recognition of $109.2 million.
• The company had a decrease in cash, cash equivalents, and marketable securities from $220.1 million as of December 31, 2024, to $185.8 million as of March 31, 2025.

Risks

• The company's success is heavily dependent on the success of its lead product candidate, CNTY-101.
• There are inherent uncertainties in the results of preliminary data, pre-clinical studies, and earlier-stage clinical trials.
• The company relies on maintaining key collaborative relationships for manufacturing and development.
• Geopolitical issues, trade disputes, banking instability, and inflation could impact the business and operations.

Future Outlook

The company estimates its cash, cash equivalents, and investments will support operations into the fourth quarter of 2026, and it remains on track to deliver clinical data for CNTY-101 by the end of 2025.

Management Comments

• We have made important progress focusing on pipeline programs with transformational potential in high-value commercial markets.
• We are on track to initiate IND-enabling studies for our lead preclinical program, CNTY-308, in mid-2025.
• Patient dosing is now underway in the U.S. for the CALiPSO-1 trial and, with expansion into Europe, we remain on track to deliver clinical data for CNTY-101 by the end of 2025.
• We look forward to building on this momentum and pursuing a disciplined approach across our pipeline to bring investigational cell therapies closer to patients and generate value for all our stakeholders.

Industry Context

Century Therapeutics is operating in the competitive cell therapy space, focusing on iPSC-derived therapies for autoimmune diseases and cancer, differentiating itself through its Allo-Evasion technology and manufacturing capabilities.

Comparison to Industry Standards

• The company's approach to developing iPSC-derived cell therapies at antibody-like scale aims to improve upon existing autologous CAR-T therapies, which face challenges in access, manufacturing consistency, and cost.
• Century's Allo-Evasion technology seeks to address the limitations of allogeneic cell therapies by enabling repeat dosing and potentially more durable responses.
• The company's focus on CD19-targeted therapies aligns with the established success of CAR-T therapies like Yescarta and Kymriah in B-cell malignancies, but Century is expanding into autoimmune diseases.
• The company is developing dual-targeted CAR-iT therapies like CNTY-341 to reduce the potential for resistance, which is a known challenge with single-target CAR-T therapies.

Stakeholder Impact

• Shareholders: The positive financial results and clinical progress are likely to be viewed favorably by shareholders.
• Patients: Advancements in clinical trials and preclinical programs offer potential new treatment options for autoimmune diseases and cancer.
• Employees: The company's progress and financial stability provide job security and opportunities for growth.
• Partners: Continued collaboration with research institutions and suppliers is essential for the company's success.

Next Steps

• Continue patient enrollment and expansion of the CALiPSO-1 clinical trial in the U.S. and Europe.
• Initiate IND-enabling studies for CNTY-308 in mid-2025.
• Commence the CARAMEL investigator-initiated trial in mid-2025.
• Report clinical data for CNTY-101 by the end of 2025.
• Advance early-stage development activities for iPSC-derived ab CAR-T cells in oncology and non-immune effector cells in high-impact diseases.

Key Dates

Keywords

iPSC, cell therapy, CNTY-101, CNTY-308, autoimmune disease, cancer, clinical trial, Allo-Evasion, Century Therapeutics, financial results